Eprosartan - Moligand™, ≥95% , Antagonist of AT 1 receptor, CAS No.133040-01-4, Antagonist of AT 1 receptor

CAS: 133040-01-4 Cat. No.: E334970 Fórmula: C₂₃H₂₄N₂O₄S Peso molecular: 424.52

CALIDAD & PUREZA Moligand™, ≥95%

Synonyms

SK&F 108566|EPROSARTAN [INN]|Eprosartan (USAN/INN)|Teveten|(E)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thienyl)methyl-2-propenoic acid|4-({2-butyl-5-[(1E)-2-carboxy-3-(2-thienyl)prop-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid|EPROSARTAN [USAN]|4-({2-butyl-5-[(1E)-2-carboxy-2-[(thiophen-2-yl)methyl]eth-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid|4-[[2-butyl-5-(2-carboxy-3-thiophen-2-ylprop-1-enyl)-1-imidazolyl]methyl]benzoic acid|SK-108566|SKB 108566|(E)-2-Butyl-1-(p-carboxybenzyl)-alpha-2-thenylimidazole-5-acrylic acid|2-Thiophenepropanoic acid, alpha-((2-butyl-1-((4-carboxyphenyl)methyl)-lH-imidazol-5-yl)methylene)-, (E)-|(alphaE)-alpha-[[2-Butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene]-2-thiophenepropanoic Acid|(E)-alpha{[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazole-5-yl]methylene}-2-thiopheneproprionic acid|EPROSARTAN [WHO-DD]|EPROSARTAN [VANDF]|Eprozar|Teveten; SK&F108566|4-({2-butyl-5-[(1E)-2-carboxy-2-(thiophen-2-ylmethyl)eth-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid|(E)-2-BUTYL-1-(P-CARBOXYBENZYL)-.ALPHA.-2-THENYLIMIDAZOLE-5-ACRYLIC ACID|(E)-3-[2-Butyl-1-[(4-carboxyphenyl)methyl]imidazol-5-yl]-2-(2-thienylmethyl)-2-propenoic acid|SK&F-108566|(E)-4-((2-butyl-5-(2-carboxy-3-(thiophen-2-yl)prop-1-enyl)-1H-imidazol-1-yl)methyl)benzoic acid|EPROSARTAN [MI]|[3H]eprosartan|[3H]-eprosartan|4-({2-butyl-5-[(1E)-2-carboxy-3-(thiophen-2-yl)prop-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid|(E)-4-((2-Butyl-5-(2-carboxy-3-(thiophen-2-yl)prop-1-en-1-yl)-1H-imidazol-1-yl)methyl)benzoic acid|Eprosartan [USAN:INN:BAN]|2-Thiophenepropanoic acid, alpha-[[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene]-, (alphaE)-|EPROSARTAN [HSDB]|(E)-alpha-[[2-Butyl-1-[(4-carboxyphenyl)-methyl]-1H-imidazol-5-yl]methylene]-2-thiophene Propanoic Acid|(E)-alpha-[[2-butyl-1-[(4carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene]-2-thiophene propanoic acid|2-THIOPHENEPROPANOIC ACID, .ALPHA.-((2-BUTYL-1-((4-CARBOXYPHENYL)METHYL)-LH-IMIDAZOL-5-YL)METHYLENE)-, (E)-|4-[[2-butyl-5-[(E)-3-hydroxy-3-oxo-2-(thiophen-2-ylmethyl)prop-1-enyl]imidazol-1-yl]methyl]benzoic acid|4-[[2-butyl-5-[(E)-2-carboxy-3-thiophen-2-ylprop-1-enyl]imidazol-1-yl]methyl]benzoic acid|Eprosartan

Storage

Store at -20°C

Shipped In

Ice chest + Ice pads

Descripción general

Eprosartan is a prototype of the imidazoleacrylic acid angiotensin II receptor antagonist which exhibits antihypertensive properties. It acts on the renin-angiotensin system in two ways to decrease total peripheral resistance. First, it blocks the binding of angiotensin II to AT1 receptors in vascular smooth muscle, causing vascular dilatation. Second, it inhibits sympathetic norepinephrine production, further reducing blood pressure.

Especificaciones

Sinónimos

SK&F 108566 | EPROSARTAN [INN] | Eprosartan (USAN/INN) | Teveten | (E)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thienyl)methyl-2-propenoic acid | 4-({2-butyl-5-[(1E)-2-carboxy-3-(2-thienyl)prop-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid | EPROSARTAN [USAN] | 4-({2-butyl-5-[(1E)-2-carboxy-2-[(thiophen-2-yl)methy Show more

Especificaciones y pureza

Moligand™, ≥95%

Condiciones de almacenamiento de almacenamiento

Store at -20°C

Enviado en

Ice chest + Ice pads

Este producto requiere envío en cadena de frío. Los servicios terrestres y otros servicios económicos no están disponibles.

Grado

Moligand™

Tipo de acción

ANTAGONIST

Mecanismo de acción

Antagonist of AT 1 receptor

Pureza

≥95%

Nombres e identificadores

Pubchem Sid

504763323

Pubchem Sid Url

https://pubchem.ncbi.nlm.nih.gov/substance/504763323

Sonrisas canónicas

CCCCC1=NC=C(N1CC2=CC=C(C=C2)C(=O)O)C=C(CC3=CC=CS3)C(=O)O

IUPAC Name

4-[[2-butyl-5-[(E)-2-carboxy-3-thiophen-2-ylprop-1-enyl]imidazol-1-yl]methyl]benzoic acid

InChIKey

OROAFUQRIXKEMV-LDADJPATSA-N

INCHI

1S/C23H24N2O4S/c1-2-3-6-21-24-14-19(12-18(23(28)29)13-20-5-4-11-30-20)25(21)15-16-7-9-17(10-8-16)22(26)27/h4-5,7-12,14H,2-3,6,13,15H2,1H3,(H,26,27)(H,28,29)/b18-12+

Isómeros SMILES

CCCCC1=NC=C(N1CC2=CC=C(C=C2)C(=O)O)/C=C(\CC3=CC=CS3)/C(=O)O

CAS alternativo

133040-01-4

Términos de entrada MeSH

2-Thiophenepropanoic acid, alpha-((2-butyl-1-((4- carboxyphenyl)methyl)-lH-imidazol-5-yl)methylene)-, (E)-;eprosartan;SK and F 108566;SKF-108566;Teveten

Peso molecular

424.52

Reaxy-Rn

14464259

Reaxys-RN_link_address

https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=14464259&ln=

Taxonomic Classification

Taxonomy Tree

• Kingdom Organic compounds
  • Superclass Benzenoids
    • Clase Benzene and substituted derivatives
      • Subclass Benzoic acids and derivatives

• Kingdom: Organic compounds
• Superclass: Benzenoids
• Clase: Benzene and substituted derivatives
• Subclass: Benzoic acids and derivatives
• Intermediate Tree Nodes: Not available
• Direct Parent: Benzoic acids
• Alternative Parents: Imidazolyl carboxylic acids and derivatives Benzoyl derivatives 1,2,5-trisubstituted imidazoles N-substituted imidazoles Dicarboxylic acids and derivatives Thiophenes Heteroaromatic compounds Carboxylic acids Azacyclic compounds Organopnictogen compounds Organonitrogen compounds Organic oxides Hydrocarbon derivatives Carbonyl compounds
• Molecular Framework: Aromatic heteromonocyclic compounds
• Substituents: Benzoic acid - 1,2,5-trisubstituted-imidazole - Benzoyl - Imidazolyl carboxylic acid derivative - Trisubstituted imidazole - Dicarboxylic acid or derivatives - N-substituted imidazole - Azole - Heteroaromatic compound - Imidazole - Thiophene - Carboxylic acid derivative - Carboxylic acid - Azacycle - Organoheterocyclic compound - Hydrocarbon derivative - Organic nitrogen compound - Carbonyl group - Organic oxide - Organic oxygen compound - Organopnictogen compound - Organooxygen compound - Organonitrogen compound - Aromatic heteromonocyclic compound
• Descripción: This compound belongs to the class of organic compounds known as benzoic acids. These are organic Compounds containing a benzene ring which bears at least one carboxyl group.
• External Descriptors: imidazoles - thiophenes - dicarboxylic acid

Data sources

1. Djoumbou Feunang Y, Eisner R, Knox C, Chepelev L, Hastings J, Owen G, Fahy E, Steinbeck C, Subramanian S, Bolton E, Greiner R, and Wishart DS. ClassyFire: Automated Chemical Classification With A Comprehensive, Computable Taxonomy. Journal of Cheminformatics, 2016, 8:61.

DOI: 10.1186/s13321-016-0174-y

Objetivos asociados (humanos)

AGTR1 Tclin Type-1 angiotensin II receptor (2 Activities)

Discover Target: AGTR1

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

ESR1 Tclin Estrogen receptor alpha (17718 Activities)

Discover Target: ESR1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

NR3C1 Tclin Glucocorticoid receptor (14987 Activities)

Discover Target: NR3C1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PGR Tclin Progesterone receptor (8562 Activities)

Discover Target: PGR

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ADRB2 Tclin Beta-2 adrenergic receptor (11824 Activities)

Discover Target: ADRB2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CHRM2 Tclin Muscarinic acetylcholine receptor M2 (10671 Activities)

Discover Target: CHRM2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ADRB1 Tclin Beta-1 adrenergic receptor (6630 Activities)

Discover Target: ADRB1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

HTR1A Tclin Serotonin 1a (5-HT1a) receptor (14969 Activities)

Discover Target: HTR1A

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ADRA2A Tclin Alpha-2a adrenergic receptor (9450 Activities)

Discover Target: ADRA2A

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

AR Tclin Androgen Receptor (11781 Activities)

Discover Target: AR

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CHRM1 Tclin Muscarinic acetylcholine receptor M1 (12690 Activities)

Discover Target: CHRM1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

DRD2 Tclin Dopamine D2 receptor (23596 Activities)

Discover Target: DRD2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

GABRA1 Tclin GABA receptor alpha-1 subunit (399 Activities)

Discover Target: GABRA1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

MAOA Tclin Monoamine oxidase A (11911 Activities)

Discover Target: MAOA

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CNR1 Tclin Cannabinoid CB1 receptor (20913 Activities)

Discover Target: CNR1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

DRD1 Tclin Dopamine D1 receptor (9720 Activities)

Discover Target: DRD1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

DRD4 Tchem Dopamine D4 receptor (7907 Activities)

Discover Target: DRD4

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PTGS1 Tclin Cyclooxygenase-1 (9233 Activities)

Discover Target: PTGS1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

SLC6A2 Tclin Norepinephrine transporter (10102 Activities)

Discover Target: SLC6A2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

HRH2 Tclin Histamine H2 receptor (5428 Activities)

Discover Target: HRH2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

HTR2A Tclin Serotonin 2a (5-HT2a) receptor (14758 Activities)

Discover Target: HTR2A

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

HTR2C Tclin Serotonin 2c (5-HT2c) receptor (11471 Activities)

Discover Target: HTR2C

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

AVPR2 Tclin Vasopressin V2 receptor (2912 Activities)

Discover Target: AVPR2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ADORA1 Tclin Adenosine A1 receptor (17603 Activities)

Discover Target: ADORA1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

AGTR1 Tclin Type-1 angiotensin II receptor (5176 Activities)

Discover Target: AGTR1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

SLC6A4 Tclin Serotonin transporter (12625 Activities)

Discover Target: SLC6A4

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CRHR1 Tclin Corticotropin releasing factor receptor 1 (2996 Activities)

Discover Target: CRHR1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ADRA1A Tclin Alpha-1a adrenergic receptor (8359 Activities)

Discover Target: ADRA1A

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PTGS2 Tclin Cyclooxygenase-2 (13999 Activities)

Discover Target: PTGS2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

HRH1 Tclin Histamine H1 receptor (7573 Activities)

Discover Target: HRH1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

OPRM1 Tclin Mu opioid receptor (19785 Activities)

Discover Target: OPRM1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

DRD3 Tclin Dopamine D3 receptor (14368 Activities)

Discover Target: DRD3

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

AVPR1A Tclin Vasopressin V1a receptor (5412 Activities)

Discover Target: AVPR1A

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

OPRD1 Tclin Delta opioid receptor (15096 Activities)

Discover Target: OPRD1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

OPRK1 Tclin Kappa opioid receptor (16155 Activities)

Discover Target: OPRK1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

HTR3A Tclin Serotonin 3a (5-HT3a) receptor (3366 Activities)

Discover Target: HTR3A

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

GCGR Tclin Glucagon receptor (2563 Activities)

Discover Target: GCGR

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

SLC6A3 Tclin Dopamine transporter (10535 Activities)

Discover Target: SLC6A3

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

GRIN1 Tclin Glutamate (NMDA) receptor subunit zeta 1 (122 Activities)

Discover Target: GRIN1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

KCNH2 Tclin HERG (29587 Activities)

Discover Target: KCNH2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CACNA1C Tclin Voltage-gated L-type calcium channel alpha-1C subunit (766 Activities)

Discover Target: CACNA1C

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PDE3A Tclin Phosphodiesterase 3A (3309 Activities)

Discover Target: PDE3A

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ESR2 Tclin Estrogen receptor beta (9272 Activities)

Discover Target: ESR2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

SLC29A1 Tclin Equilibrative nucleoside transporter 1 (1711 Activities)

Discover Target: SLC29A1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CHRM4 Tclin Muscarinic acetylcholine receptor M4 (6041 Activities)

Discover Target: CHRM4

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CHRM5 Tclin Muscarinic acetylcholine receptor M5 (4677 Activities)

Discover Target: CHRM5

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ADRA2B Tclin Alpha-2b adrenergic receptor (4412 Activities)

Discover Target: ADRA2B

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ADRA2C Tclin Alpha-2c adrenergic receptor (4876 Activities)

Discover Target: ADRA2C

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CHRM3 Tclin Muscarinic acetylcholine receptor M3 (7750 Activities)

Discover Target: CHRM3

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

DRD5 Tchem Dopamine D5 receptor (1597 Activities)

Discover Target: DRD5

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ADRB3 Tclin Beta-3 adrenergic receptor (5850 Activities)

Discover Target: ADRB3

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Objetivos asociados (no humanos)

Htr7 Serotonin 7 (5-HT7) receptor (19 Activities)

Discover Target: Htr7

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Agtr2 Angiotensin II type 2 (AT-2) receptor (803 Activities)

Discover Target: Agtr2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Mc4r Melanocortin receptor 4 (1205 Activities)

Discover Target: Mc4r

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Agtr1b Type-1B angiotensin II receptor (525 Activities)

Discover Target: Agtr1b

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Npy1r Neuropeptide Y receptor type 1 (8 Activities)

Discover Target: Npy1r

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Cckar Cholecystokinin A receptor (90 Activities)

Discover Target: Cckar

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Ntsr1 Neurotensin receptor 1 (48 Activities)

Discover Target: Ntsr1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Pde4d Phosphodiesterase 4D (4 Activities)

Discover Target: Pde4d

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Bdkrb1 Bradykinin B1 receptor (77 Activities)

Discover Target: Bdkrb1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Hdac6 Histone deacetylase 6 (222 Activities)

Discover Target: Hdac6

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PDE6A Phosphodiesterase 6A (40 Activities)

Discover Target: PDE6A

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Agtr1 Type-1A angiotensin II receptor (520 Activities)

Discover Target: Agtr1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Canis familiaris (36305 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Oryctolagus cuniculus (11301 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Rattus norvegicus (775804 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Plasma (328 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Agtr1b Angiotensin II receptor (1735 Activities)

Discover Target: Agtr1b

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Agtr1b Angiotensin II receptor (AT-1) type-1 (1480 Activities)

Discover Target: Agtr1b

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Mecanismos de acción

Propiedades químicas y físicas

• Solubilidad: Soluble in Chloroform: Methanol; 1: 1 mixture
• Punto de fusión (°C): >246° C (dec.)
• Peso molecular: 424.500 g/mol
• XLogP3: 4.500
• Hydrogen Bond Donor Count: 2
• Hydrogen Bond Acceptor Count: 6
• Rotatable Bond Count: 10
• Exact Mass: 424.146 Da
• Monoisotopic Mass: 424.146 Da
• Topological Polar Surface Area: 121.000 Ų
• Heavy Atom Count: 30
• Formal Charge: 0
• Complexity: 618.000
• Isotope Atom Count: 0
• Defined Atom Stereocenter Count: 0
• Undefined Atom Stereocenter Count: 0
• Defined Bond Stereocenter Count: 1
• Undefined Bond Stereocenter Count: 0
• The total count of all stereochemical bonds: 1
• Covalently-Bonded Unit Count: 1

Application Protocols

No vendor-tested protocols are provided for this specific SKU. The following are general, literature-style suggestions for using a small-molecule AT1 receptor ligand as a research tool. Adjust to your system.

• Stock solutions:

  • Dissolve in anhydrous DMSO to 10–50 mM. Vortex and, if needed, sonicate briefly. Filter through 0.2 µm PTFE. Store aliquots at −20°C.

• Radioligand binding (membranes or cells expressing AT1):

  • Prepare serial dilutions (10-point, 0.1 nM–30 µM final). Maintain constant DMSO (e.g., 0.5% v/v) across wells.
  • Incubate with a fixed concentration of [125I]-angiotensin II tracer at 25°C for 60–90 min (or per tracer’s equilibrium time). Separate bound/free (rapid filtration) and quantify. Fit competition curves (Cheng–Prusoff) to estimate Ki.

• Functional antagonism (Ca2+ flux or IP1):

  • Pre-incubate cells with antagonist (e.g., 10 nM–10 µM) for 15–30 min, then stimulate with an EC80 concentration of angiotensin II. Record responses. Generate concentration–response to estimate apparent potency.

• SPR/BLI (immobilized receptor fragments or reconstituted particles):

  • Run multi-cycle kinetics with 5–7 concentrations spanning expected KD. Include reference surfaces and solvent correction.

These protocols are illustrative only. Optimize ligand concentrations, incubation times, temperature, and buffers for your assay platform. Always include appropriate positive/negative controls and verify compound solubility/stability under assay conditions.

Biological Roles

Biochemical context (literature/general):

• Eprosartan is a well-characterized small-molecule ligand of the renin–angiotensin system (RAS), binding selectively to the angiotensin II type 1 (AT1) receptor. By occupying the AT1 binding pocket, such ligands antagonize angiotensin II signaling in cellular/biochemical systems, enabling mechanistic studies of RAS signaling.
• Target class: Class A GPCR (AT1). Ligand engagement modulates downstream effectors (e.g., Gq/11 pathways, phospholipase C activation, intracellular Ca2+ mobilization). In research, eprosartan is frequently used to benchmark antagonist potency and selectivity among ARBs.
• Selectivity considerations: ARBs typically show high selectivity for AT1 over AT2 in binding assays; confirm with your assay species and receptor constructs. Off-target profiling is recommended in broad receptor panels if used as a tool compound in chemical biology.

Experimental uses (research-only):

• Radioligand competition assays using [125I]-[Sar1,Ile8]-AngII or other tracers to determine Ki/IC50.
• Functional antagonism studies in cell lines expressing AT1, monitoring IP1 accumulation, Ca2+ flux, or ERK phosphorylation.
• Structural biology adjunct: saturation-binding or co-crystallization experiments with AT1 fragments, nanodiscs, or thermostabilized mutants (case-dependent; literature reports exist for ARB-bound receptor structures).

Caveat: The above roles are literature-based descriptions of the compound class. No medical or clinical claims are made; SKU E334970 is supplied strictly for research use only.

Buffer Applications

This item is not a buffering reagent and is not typically used to prepare buffer systems.

• Practical note: If using eprosartan in biochemical assays, prepare the compound in a suitable organic cosolvent (e.g., DMSO) and dilute into your pre-selected assay buffer (e.g., HEPES, Tris, or phosphate-based systems at the pH optimal for your biology). Maintain a constant final cosolvent percentage across control and treated samples to avoid solvent-induced artifacts.

• Solubility assists (general): Slightly basic buffers (pH above the acidic pKa) can increase apparent solubility of acidic ligands; however, ensure that the pH does not perturb receptor function or assay readouts.

No item-specific buffer recipes or buffering capacities are provided for SKU E334970.

Green Alternatives

While eprosartan is not itself a solvent or bulk reagent, its handling and derivatization often involve organic solvents. Consider greener solvent choices where feasible, balancing solubility needs and assay constraints.

• General strategy:

  • Prefer high–boiling point, low–toxicity, bio-based or recyclable solvents for workups and processing, and minimize DMSO/DMF volumes consistent with your solubility needs.

• Example comparisons (general/literature guidance; validate for your system):

  | Use case | Conventional choice | Greener alternative | Trade-offs | |---|---|---|---| | Preparing concentrated stocks | DMSO | Cyrene or propylene carbonate | Solubility can be lower; viscosity may complicate pipetting; assay compatibility to be validated. | | Reaction medium for amide coupling | DMF or NMP | 2-MeTHF, ethyl acetate, CPME | May require base and coupling system optimization; limited solubility of polar reagents. | | Workup/extraction | Dichloromethane | EtOAc or MTBE | Partitioning may change; emulsions possible. | | Crystallization | Acetone/ACN | Green alcohols (EtOH/i-PrOH) | Solubility differences require screening. |

• Process intensification:

  • Explore solventless film hydration for stock preparation before aqueous dilution, or use minimal cosolvent with surfactants to reduce DMSO load in biology.

Always ensure that greener substitutions do not compromise analytical integrity, target binding, or material stability. No item-specific solvent restrictions are specified for SKU E334970.

Pharmaceutical Uses

Research/formulation context only (no therapeutic claims):

• Eprosartan is known in the literature as an angiotensin receptor ligand that has been formulated as various salt forms (e.g., mesylate) for improved processability and dissolution. For research and preformulation studies, the free acid can be used to explore:
  • Salt screening to alter solubility and crystallinity (e.g., mesylate, besylate, maleate—subject to counterion suitability for your application).
  • Solid-state characterization (XRPD, DSC/TGA) to understand polymorphism and hydrate/solvate formation.
  • Particle engineering (milling, spray-drying) and amorphous solid dispersions with polymer carriers (e.g., PVP/VA, HPMCAS) to enhance apparent solubility.
  • In vitro dissolution modeling using biorelevant media to benchmark ARB-class behavior.

Analytical quality controls (non-pharmacopeial for this catalog item):

• Establish validated LC–UV/LC–MS methods for assay/content uniformity, related substances, and stability-indicating behavior under ICH stress (acid/base, oxidative, photolytic, and thermal conditions). Note that no pharmacopeial compliance is claimed for SKU E334970.

Excipients/compatibilities (general):

• For research formulations, evaluate compatibility with common excipients (lactose, MCC, mannitol) and with wet granulation solvents. Acidic ARB ligands may interact with basic excipients; maintain pH control to mitigate degradation.

Reminder: This product is for laboratory research only and is not supplied for human or veterinary use.

Physical Properties

Item-specific properties provided in this listing are limited; definitive specifications should be taken from the CoA/SDS.

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight (spec for this lot): Not specified for this item; refer to CoA/Spec Sheet.
• Molecular formula (spec for this lot): Not specified for this item; refer to CoA/Spec Sheet.

Literature/general physical data for eprosartan (free acid or non-salt form; values may vary by form and lot — for reference only):

• Physical state: typically a solid organic compound with low volatility.
• Solubility profile: sparingly soluble in water in the neutral/free-acid form; readily soluble in polar aprotic organic solvents such as DMSO and DMF, and soluble in alcohols upon basification or salt formation (literature/general).
• Ionization: contains a strongly acidic function (pKa for the acidic group often in the 3–5 range for related ARB acids/tetrazoles; check primary references for the exact value of eprosartan) (literature/general).
• Partitioning: designed to be lipophilic for receptor binding; logP/logD values are typically moderate-to-high for ARBs (literature/general reference only).

Important: Do not use the above literature notes as product specifications. Always consult the CoA/SDS for the exact values applicable to SKU E334970.

Quality and Grades

• Grade/Purity (item-specific): Moligand™.

What Moligand™ implies (general description of grade intent):

• This designation is used at Aladdin Scientific for high-purity, small-molecule ligands intended for research on target engagement, binding assays, and biochemical/biophysical studies. It emphasizes suitability for ligand discovery workflows, structural biology adjuncts, and pharmacology research.
• Typical expectations for such a grade (not specifications for this item):
  • High chemical purity verified by orthogonal methods (e.g., HPLC/UPLC and NMR).
  • Identity confirmation versus reference standards.
  • Low residual solvents and water appropriate for sensitive assays.
  • Documentation support for reproducible assay performance.
• UV cutoff, trace metals, water/peroxide content: Not specified for this item; refer to CoA/Spec Sheet.

Implications for use:

• Researchers can employ this material as a reference ligand/control compound in AT1 receptor binding or functional assays, or as a comparator in medicinal chemistry SAR series.
• If your application is chromatographic (e.g., quantitative reference in LC-MS), request the CoA chromatograms and impurity profile to confirm suitability for your method’s detection wavelength and ionization mode.

Note: If you require pharmacopeial compliance or certified reference material status, contact us prior to purchase; Moligand™ is supplied for research use only and is not a pharmacopoeial or clinical grade.

Reaction and Applications

This product is primarily intended as a research ligand and small-molecule standard rather than as a general-purpose reagent. Typical research applications include:

• Reference ligand/control:
  • Use as a positive control in AT1 receptor binding assays, radioligand displacement, functional second-messenger assays, or label-free biosensing (SPR/BLI/ITC). Establish a concentration–response curve to benchmark assay quality (literature/general).
• Analytical standard:
  • Calibration and system suitability standard in LC-UV or LC–MS method development for ARB class quantitation; verify extinction coefficients and ionization parameters for your instrument (no item-specific UV data provided).
• Chemical biology and probe development (concepts):
  • Derivatization via the acidic function to generate amide/ester conjugates for immobilization on affinity matrices or introduction of reporter tags (fluorophores/biotin) for pull-downs and imaging (literature/general).
• Solid-state and preformulation research:
  • Salt screening (e.g., mesylate and other pharmaceutically acceptable salts), co-crystal exploration, and polymorph studies to understand structure–property relationships (literature/general).

Practical tips:

• Prepare fresh DMSO stocks; minimize freeze–thaw cycles to preserve assay reproducibility.
• Filter organic solutions (0.2 µm PTFE) to remove particulates before microscale biophysical runs.
• For coupling chemistry, use anhydrous conditions and dry solvents; free acids can be activated with standard peptide-coupling reagents for amide formation to linkers or resins (see Synthetic Utility and Reaction Conditions).

Note: No medical/clinical use is implied; this item is for research use only.

Reaction Conditions

General conditions for derivatizing an acidic, lipophilic ligand such as eprosartan (research-only guidance; verify experimentally):

• Amide coupling (to introduce linkers/tags):

  • Solvent: dry DMF, DCM, or 2-MeTHF/EtOAc (with solubility aids).
  • Reagents: HATU or COMU (1.1–1.5 eq), DIPEA or collidine (2–3 eq); or EDC·HCl (1.2–1.5 eq) with HOAt/HOBt analogs and base.
  • Temperature/time: 0–25°C, 1–16 h depending on nucleophile reactivity.
  • Tips: Pre-form active ester at 0–5°C; add amine slowly to control exotherm. Monitor by LC–MS.

• Esterification:

  • Steglich: DCC (1.1–1.3 eq), catalytic DMAP in DCM at 0–25°C, 2–12 h.
  • Fischer: Alcohol solvent with catalytic acid (e.g., H2SO4 or p-TsOH), azeotropic water removal; ensure heteroaromatic stability.

• NHS ester formation:

  • Reagents: N-hydroxysuccinimide (1.2–1.5 eq) with DCC or EDC in DCM/DMF; 0–25°C, 1–4 h. Isolate and store cold, protected from moisture.

• Purification:

  • Reverse-phase prep HPLC for polar conjugates; normal-phase chromatography (silica) for neutral esters/analogs.

• Stability checks:

  • Avoid strong bases and prolonged high temperatures that may induce decarboxylation or heteroaryl degradation.
  • Conduct photostability tests; protect solutions from intense light if chromophores are present.

These are literature-style conditions for generic carboxylate chemistry. No item-specific reactivity or stability specs are provided for SKU E334970; confirm all conditions on small scale first.

Safety and Handling

Safety information specific to this item is limited in the Product Data and must be confirmed in the official SDS.

• GHS classification, signal word, pictograms, and H-statements: Not specified for this item; refer to SDS.
• Likely hazards (general/literature for small-molecule aromatic acids/heteroaryls): may cause irritation to skin, eyes, and respiratory tract upon exposure to dust or solutions; avoid inhalation and contact (not product-specific; defer to SDS).

Good laboratory practices (general):

• Engineering controls: Use in a fume hood or well-ventilated area to minimize dust/aerosol exposure.
• Personal protective equipment: lab coat, safety glasses, and appropriate chemically resistant gloves (e.g., nitrile). Consider double-gloving for prolonged handling of DMSO solutions.
• Hygiene: wash hands thoroughly after handling; avoid eating/drinking in the lab.

Handling and incompatibilities (general guidance):

• Avoid strong oxidizers until compatibility is assessed.
• For carboxylic-acid-containing compounds, avoid prolonged contact with strong bases unless salt formation is intended; monitor for hydrolysis if esters are prepared as intermediates.
• Some ARB-type compounds may exhibit light sensitivity; protect from strong light as a precaution.

First aid overview (consult SDS for definitive procedures):

• Skin/eye contact: rinse with copious water for at least 15 minutes; remove contaminated clothing; seek medical attention if irritation persists.
• Inhalation: move to fresh air; monitor breathing; seek medical advice if symptoms occur.
• Ingestion: rinse mouth; do not induce vomiting unless directed by medical personnel.

Waste: Dispose of according to institutional and local regulations; avoid discharge to the environment without treatment.

Solvent Selection

Solubility characteristics and solvent choices depend strongly on the compound form (free acid vs. salt) and assay needs. The following guidance is general to ARB-like acidic, lipophilic ligands and should be validated for your lot.

• Primary stock preparation (common practice):
  • DMSO: typically the first choice for concentrated stocks (e.g., 10–50 mM) due to excellent solubilizing power for lipophilic acids (literature/general).
  • DMF or NMP: alternatives when DMSO interference is a concern in biophysical methods.
• Aqueous use:
  • Direct water solubility is usually low for the neutral/free-acid form. Dilute DMSO stocks into aqueous assay buffers while maintaining final DMSO ≤0.1–1% v/v as your biology tolerates.
  • Adjusting pH above the acidic pKa or using co-solvents/surfactants (e.g., 0.05–0.1% Tween 80) can improve apparent solubility; confirm that additives do not perturb the assay readout (literature/general).
• Alcohols:
  • Ethanol or isopropanol can be useful intermediates for film-casting or pre-wetting steps prior to buffer addition.
• Salts and basification:
  • Transient formation of soluble salts (e.g., triethanolammonium) can assist with aqueous formulation for certain biophysical assays; ensure counterions do not interfere.

Mini comparison (general):

• DMSO: maximal solvation power; may affect certain targets and spectroscopy at higher percentages.
• DMF: strong solvent; more challenging toxicologically and for disposal.
• 2-MeTHF/ethyl acetate: greener options but usually insufficient alone for highly lipophilic acids in concentrated stocks.

Always confirm actual solubility for SKU E334970 experimentally; no item-specific solubility data are provided in this listing.

Storage and Reconstitution

Item-specific storage and shipping:

• Storage conditions (from Product Data): Store at −20°C.
• Shipped in (from Product Data): Ice chest + ice pads.

General handling and reconstitution guidance:

• Upon receipt: Allow the sealed container to equilibrate to room temperature before opening to avoid moisture condensation. If supplied as a solid, protect from ambient humidity by handling in a dry environment; promptly reseal with desiccant.
• Long-term storage: Keep tightly closed at −20°C in a desiccated, dark environment. Avoid repeated warming/cooling; dispense into single-use aliquots if feasible.
• Stock solution preparation (research use):
  • Dissolve in anhydrous DMSO to prepare a 10–50 mM stock. Mix thoroughly. If necessary, apply brief bath sonication. Verify clarity; if precipitation persists, lower concentration or switch to DMF/NMP.
  • Optional: Prepare salt forms in situ by adding a slight molar excess of a volatile amine (e.g., triethylamine) to enhance solubility in certain organic solvents; remove base prior to sensitive applications if required.
• Storage of solutions: Aliquot stocks into inert vials (amber, low-bind). Store at −20°C. Minimize freeze–thaw cycles; use each aliquot once. Typical recommended maximum storage time for DMSO stocks is weeks to a few months; confirm stability by LC as needed.
• Aqueous working solutions: Prepare immediately before use by diluting the organic stock into buffer. Maintain consistent final cosolvent percentage across controls and treatments.

Note: No item-specific stability-indicating data are provided. For critical work, establish in-house stability and solubility profiles under your exact conditions.

Structure and Identity

Brief overview: Eprosartan is a small-molecule angiotensin II type-1 (AT1) receptor ligand commonly supplied for biochemical and medicinal chemistry research. The entry below separates item-specific catalog facts from general/literature information.

• Item-specific identifiers (from Product Data):

  • SKU: E334970
  • Product name: Eprosartan
  • CAS: 133040-01-4
  • CID: 5281037 (PubChem)
  • InChIKey: 265538 (as provided; appears abbreviated—consult CoA/SDS for the full 27-character InChIKey)
  • SMILES: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.

• Structural features (general/literature description of the eprosartan free acid):

  • Functional groups: aromatic heterocycles, a strongly acidic functionality (carboxylic acid/acidic heteroaryl), and lipophilic aryl systems typical of angiotensin receptor ligands.
  • Polarity profile: amphiphilic with a dominant hydrophobic core and one or more acidic groups that deprotonate at physiological pH (literature/general).
  • Stereochemistry: eprosartan is typically supplied as an achiral molecule (literature/general).

• 2D structure description in words (literature/general):

  • A fused or linked aryl/heteroaryl scaffold bearing an acidic terminus and a lipophilic side chain; the design mimics angiotensin II pharmacophore elements and supports high-affinity binding to AT1 receptors. No atom-specific connectivity is asserted for this catalog item; consult the CoA/SDS or primary literature for exact structure drawings.

Note: For any compliance, purity assignment, and definitive identifiers (full SMILES/InChI), please refer to the item’s CoA/Spec Sheet.

Synthetic Utility

Although primarily used as a tool ligand/standard, eprosartan can serve as a substrate for derivatization in chemical biology and materials interfaces.

• Functional group leverage (general):

  • Acidic functionality enables classical transformations:
    • Amide coupling to linkers, resins, fluorophores, or affinity tags (e.g., EDC/HOBt, HATU, COMU; see Reaction Conditions).
    • Esterification (Steglich or Fischer) to generate protected forms or prodrug-like esters for mechanistic transport studies (research-only).
  • Aromatic/heteroaromatic sites may permit late-stage C–H functionalization under mild conditions for probe diversification, pending selectivity.

• Immobilization strategies:

  • Convert the acid to NHS esters for rapid conjugation to amines on beads or surfaces.
  • Introduce spacers (PEGylated diamines) through amide bonds to reduce steric occlusion in binding assays on solid supports.

• Analytical tagging:

  • Incorporate photoaffinity groups (diazirines/aryl azides) via amide linkages for target identification workflows; pair with biotin/alkyne handles for enrichment and click chemistry.

• Retrosynthetic note:

  • If custom analogs are pursued, maintain the acidic motif and key lipophilic vectors known to drive AT1 engagement, while exploring vector modifications for selectivity profiling (SAR). Literature on ARB pharmacophores can guide which vectors tolerate substitution.

Caution: Reaction conditions must be screened to avoid degrading sensitive heteroaromatic moieties; confirm structure and purity of derivatives by NMR, HRMS, and LC.

Target Specificity

Item-specific target validation data are not provided in the Product Data for SKU E334970.

General/literature context for research planning:

• Primary target class: Angiotensin II type 1 receptor (AT1), a class A GPCR in the renin–angiotensin system.
• Mode of action: antagonist/competitive ligand at the orthosteric site in typical assays.
• Off-targets: ARB scaffolds are generally selective for AT1 over AT2; however, specificity should be confirmed across receptor families relevant to your model.

For definitive specificity metrics (Ki, IC50, selectivity ratios) applicable to your assay species and conditions, consult primary literature or generate fresh benchmarking data alongside your experimental controls. No target-binding data are certified for this catalog item.